# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Olivia Brayer reiterates Gilead Sciences (NASDAQ:GILD) with a Neutral and maintains $70 price target.
The collaboration plans to evaluate the combination of Marengo's first-in-class TCR Vβ selective dual T cell agonist, STAR0...
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...
Piper Sandler analyst Joseph Catanzaro maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $95 price tar...